<code id='06AE2B3208'></code><style id='06AE2B3208'></style>
      • <acronym id='06AE2B3208'></acronym>
      <center id='06AE2B3208'><center id='06AE2B3208'><tfoot id='06AE2B3208'></tfoot></center><abbr id='06AE2B3208'><dir id='06AE2B3208'><tfoot id='06AE2B3208'></tfoot><noframes id='06AE2B3208'>
      • <optgroup id='06AE2B3208'><strike id='06AE2B3208'><sup id='06AE2B3208'></sup></strike><code id='06AE2B3208'></code></optgroup>
        5. <b id='06AE2B3208'><label id='06AE2B3208'><select id='06AE2B3208'><dt id='06AE2B3208'><span id='06AE2B3208'></span></dt></select></label></b><u id='06AE2B3208'></u>
          <i id='06AE2B3208'><strike id='06AE2B3208'><tt id='06AE2B3208'><pre id='06AE2B3208'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / knowledge / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-28 04:35:02 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：hotspot   
                                        
                                      
                                      Page View：332
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs
                                
                            
          Next article：  
                                      
                                          Heart attack and stroke risk calculators need revising
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles